RxDoctor Payments Data

Altaf Ali, MD

Interventional Cardiology · Chino, CANPI 1376722736

Payments from drug & device makers

$304in general payments, 2019–2025

Across 10 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$163
  • Pfizer$27
  • Novartis$25
  • E.r. Squibb & Sons, L.L.C.$23
  • Merck$22
  • Scpharmaceuticals Inc.$19
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$28293%
  • Education$227%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304 in reported general payments places this provider in the 5th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$184,958
Medicare patients
341
Services billed
2,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban356$437,243
EntrestoSacubitril/Valsartan164$207,262
XareltoRivaroxaban120$121,333
FarxigaDapagliflozin Propanediol124$114,766
JardianceEmpagliflozin93$113,270
BrilintaTicagrelor23$29,146
Ranolazine ErRanolazine262$23,056
DapagliflozinDapagliflozin Propanediol18$14,923
Metoprolol Succinate757$13,265
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide489$6,985
Carvedilol795$6,442
Atorvastatin Calcium424$4,667
Losartan Potassium422$3,686
Diltiazem 24hr ErDiltiazem Hcl94$3,559
Amlodipine Besylate593$2,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$437,243356 claims
NovartisEntresto$25$207,262164 claims
AstraZenecaFarxiga, Brilinta$163$143,912147 claims
Boehringer IngelheimJardiance$12$113,27093 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →